Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698276 | 0.85 | MAPK1 (0.56) | ALDH1A1MAPK1GAAALOX15MEN1 | |
| SCHEMBL2434012 | 0.84 | ALDH1A1 (0.89) | ALDH1A1MAPK1GAAALOX15MEN1 | |
| SCHEMBL12417672 | 0.81 | NR1H2 (0.54) | ALDH1A1MAPK1GAAALOX15NR1H2 | |
| SCHEMBL31180529 | 0.80 | NR1H2 (0.47) | ALDH1A1MAPK1GAAALOX15NR1H2 | |
| SCHEMBL2432352 | 0.80 | ALDH1A1 (0.97) | ALDH1A1MAPK1GAAALOX15MEN1 | |
| SCHEMBL13613772 | 0.79 | ALDH1A1 (0.62) | ALDH1A1MAPK1GAAALOX15MEN1 | |
| SCHEMBL696762 | 0.78 | MAPK1 (0.54) | ALDH1A1MAPK1GAAALOX15MEN1 | |
| SCHEMBL13857264 | 0.77 | MAPK1 (0.53) | ALDH1A1MAPK1GAAALOX15MEN1 | |
| SCHEMBL696832 | 0.76 | MAPK1 (0.47) | ALDH1A1MAPK1GAAALOX15MEN1 | |
| SCHEMBL696571 | 0.75 | MAPK1 (0.51) | ALDH1A1MAPK1GAAALOX15MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720040-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | Lario Therapeutics Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246522-A1 | SULFONAMIDE COMPOUNDS BENEFICIAL IN NEUROPROTECTIVE TREATMENT | LARIO THERAPEUTICS LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-110914242-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-2421612-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | Novartis AG (CH) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011067348-A2 | MEK INHIBITOR SALTS AND SOLVATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067348-A2 | MEK INHIBITOR SALTS AND SOLVATES THEREOF | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011067356-A2 | POLYMORPHS OF A MEK INHIBITOR | NOVARTIS AG (CH) | 2011-06-09 | — | — | WO | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121646-A1 | HETEROCYCLIC COMPOUNDS AS MEK INHIBITORS | NOVARTIS AG (CH) | 2010-10-28 | — | — | WO | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| EP-0699201-A1 | SUBSTITUTED METHYLENEDIOXY 3',4':6,7]INDOLIZINO- 1,2-$i(b)]QUINOLINONES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-03-06 | — | — | EP | disclosed |
| EP-0699201-A4 | SUBSTITUTED METHYLENEDIOXY 3',4':6,7]INDOLIZINO- 1,2--i(b)]QUINOLINONES | SMITHKLINE BEECHAM CORP (US) | 1996-01-22 | — | — | EP | disclosed |
| WO-1994025465-A1 | SUBSTITUTED METHYLENEDIOXY[3',4':6,7]INDOLIZINO-[1,2-b]QUINOLINONES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180312523-A1 | Propionic Acid Derivatives and Methods of Use Thereof | ITGB3, ITGA1, ITGB5 | ALDH1A1 263/4885MAPK1 1849/4885GAA 2874/4885 |
| US-20090275606-A1 | Heterocyclic Compounds as MEK Inhibitors | NRAS, BRAF, MAP3K1 | ALDH1A1 1214/4885MAPK1 5/4885GAA 3410/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | ALDH1A1 263/4885MAPK1 1849/4885GAA 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.